PMID- 37190924
OWN - NLM
STAT- MEDLINE
DCOM- 20230712
LR  - 20230712
IS  - 1757-5672 (Electronic)
IS  - 1757-5664 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Jul
TI  - Efficacy and safety of the Rezum system for the treatment of catheter-dependent 
      urinary retention: Three-year real-world outcomes in a multimorbid, multiethnic 
      population.
PG  - 148-153
LID - 10.1111/luts.12482 [doi]
AB  - OBJECTIVES: To evaluate the long-term real-world efficacy and safety of Rezum for 
      the treatment of catheter-dependent urinary retention in a multimorbid, 
      multiethnic population. METHODS: A single-office, retrospective study was 
      conducted on patients treated with Rezum between 2017 and 2019. Patients were 
      included if they had catheter-dependent urinary retention prior to treatment and 
      at least one follow-up within 36 months postoperatively. Patient demographics, 
      procedural characteristics, adverse events (AEs), and outcome measures, including 
      benign prostate hyperplasia (BPH) medication usage and postvoid residual (PVR), 
      were collected at 3, 6, 12, and/or 36 months postoperatively. Regret was assessed 
      at 36 months using the 5-item Decisional Regret Scale (DRS). RESULTS: A total of 
      27 patients met the inclusion criteria, with the majority being Asian (29.6%), 
      followed by non-Hispanic Black (26.0%) and Hispanic (22.2%). Most patients 
      (77.8%) had at least one comorbidity. Trial of void (TOV) was attempted at a 
      median of 8 days (7, 13). Fourteen patients (51.9%) failed their initial TOV. 
      Median time until catheter independence was 13.5 days (8.5, 28.8). Common AEs 
      included urinary retention (51.9%), urinary tract infections (UTIs) (25.9%), and 
      dysuria (25.9%). All cases of UTIs (7/7) and most cases of dysuria (6/7) occurred 
      in patients who failed their initial TOV. At 36 months, there was a significant 
      median percentage change in PVR (-100.0% [-100.0, -36.7], p = .049), and 40.4% of 
      patients discontinued their BPH medications (p = .001). Of the 11 patients who 
      filled out the DRS, 10 (90.9%) agreed/strongly agreed that they made the right 
      decision. By 36 months, 4 patients (14.8%) underwent reoperation and 24 (88.9%) 
      remained catheter-independent. CONCLUSIONS: At long-term follow-up, Rezum 
      effectively treated catheter-dependent urinary retention with minimal decisional 
      regret. In patients with urinary retention, urologists should consider delaying 
      TOV until 2 weeks postoperatively to maximize the likelihood of a successful TOV 
      and minimize the risk of AEs.
CI  - (c) 2023 John Wiley & Sons Australia, Ltd.
FAU - Babar, Mustufa
AU  - Babar M
AUID- ORCID: 0000-0001-8490-2260
AD  - Albert Einstein College of Medicine, Bronx, New York, USA.
AD  - DSS Urology, Queens Village, New York, USA.
FAU - Masoud, Zaki
AU  - Masoud Z
AD  - Albert Einstein College of Medicine, Bronx, New York, USA.
FAU - Labagnara, Kevin
AU  - Labagnara K
AUID- ORCID: 0000-0003-3275-1004
AD  - Albert Einstein College of Medicine, Bronx, New York, USA.
FAU - Loloi, Justin
AU  - Loloi J
AD  - Department of Urology, Montefiore Medical Center, Bronx, New York, USA.
FAU - Sayed, Rahman
AU  - Sayed R
AD  - Albert Einstein College of Medicine, Bronx, New York, USA.
FAU - Singh, Sandeep
AU  - Singh S
AD  - DSS Urology, Queens Village, New York, USA.
FAU - Tang, Kevin
AU  - Tang K
AUID- ORCID: 0000-0002-2908-1954
AD  - Albert Einstein College of Medicine, Bronx, New York, USA.
FAU - Syed, Umar
AU  - Syed U
AD  - DSS Urology, Queens Village, New York, USA.
FAU - Ciatto, Michael
AU  - Ciatto M
AD  - DSS Urology, Queens Village, New York, USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20230515
PL  - Australia
TA  - Low Urin Tract Symptoms
JT  - Lower urinary tract symptoms
JID - 101506777
SB  - IM
MH  - Humans
MH  - Male
MH  - Dysuria
MH  - *Lower Urinary Tract Symptoms/surgery
MH  - *Prostatic Hyperplasia/complications/surgery
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Urinary Retention/etiology/therapy
MH  - *Urinary Tract Infections/etiology
OTO - NOTNLM
OT  - benign prostatic hyperplasia
OT  - lower urinary tract symptoms
OT  - minimally invasive surgical therapy
OT  - urinary catheter
OT  - urinary retention
EDAT- 2023/05/16 06:42
MHDA- 2023/07/04 06:42
CRDT- 2023/05/16 03:50
PHST- 2023/04/18 00:00 [revised]
PHST- 2023/02/10 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/07/04 06:42 [medline]
PHST- 2023/05/16 06:42 [pubmed]
PHST- 2023/05/16 03:50 [entrez]
AID - 10.1111/luts.12482 [doi]
PST - ppublish
SO  - Low Urin Tract Symptoms. 2023 Jul;15(4):148-153. doi: 10.1111/luts.12482. Epub 
      2023 May 15.